Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 6 de 6
1.
Surgery ; 172(6): 1606-1613, 2022 12.
Article En | MEDLINE | ID: mdl-35989132

BACKGROUND: The patients with unresectable perihilar cholangiocarcinoma require biliary drainage to relieve symptoms and allow for palliative systemic chemotherapy. The aim of this study was to establish the success, complication, and mortality rates of the initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma at presentation. METHODS: In this retrospective multicenter study, patients with unresectable perihilar cholangiocarcinoma who underwent initial endoscopic or percutaneous transhepatic biliary drainage between 2002 and 2014 were included. The success of drainage was defined as a successful biliary stent or drain placement, no unscheduled reintervention within 14 days, and serum bilirubin levels <50 µmol/L (ie, 2.9 mg/dL) or a >50% decrease in serum bilirubin after 14 days. Severe complications, and 90-day mortality were recorded. RESULTS: Included were 186 patients: 161 (87%) underwent initial endoscopic biliary drainage and 25 (13%) underwent initial percutaneous transhepatic biliary drainage. The success of initial drainage was observed in 73 patients (45%) after endoscopic biliary drainage and 6 (24%) after percutaneous transhepatic biliary drainage. The reasons for an unsuccessful initial drainage were: the failure to place a drain or stent in 39 patients (21%), an unplanned reintervention within 14 days in 52 patients (28%), and the bilirubin level >50 µmol/L (or not halved) after 14 days of initial drainage in 16 patients (9%). Severe drainage-related complications occurred in 19 patients (12%) after endoscopic biliary drainage and in 3 (12%) after percutaneous transhepatic biliary drainage. Overall, 66 patients (36%) died within 90 days after initial biliary drainage. CONCLUSION: Initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma had a success rate of 45% and a 90-day mortality rate of 36%. Future studies for patients with perihilar cholangiocarcinoma should focus on improving biliary drainage.


Bile Duct Neoplasms , Cholangiocarcinoma , Klatskin Tumor , Humans , Klatskin Tumor/surgery , Klatskin Tumor/complications , Bile Duct Neoplasms/surgery , Bile Duct Neoplasms/complications , Cholangiocarcinoma/surgery , Drainage/adverse effects , Stents/adverse effects , Retrospective Studies , Bile Ducts, Intrahepatic/pathology , Bilirubin , Treatment Outcome
2.
Surg Laparosc Endosc Percutan Tech ; 27(4): 253-256, 2017 Aug.
Article En | MEDLINE | ID: mdl-28708769

PURPOSE: The purpose of this study is to evaluate knowledge about management of percutaneous transhepatic biliary drainage (PTBD) catheters among nurses taking care of hepato-pancreato-biliary (HPB) patients. METHODS: Six HPB nurses from the Dutch national HPB association created a questionnaire that was complemented by 2 HPB surgeons, 3 HPB interventional radiologists, and a methodologist. Registered nurses working at the department of gastroenterology or gastrointestinal surgery and familiar with the care for HPB patients were invited to complete the questionnaire. RESULTS: In total 120 completed questionnaires from Dutch nurses were returned. The responders were working in 38 of 64 different hospitals. About half of the respondents considered their own knowledge insufficient, which was reflected in the response to the specific questions concerning the PTBD procedure, and 70% rated the knowledge of their immediate nursing colleagues as insufficient. Less than 50% of the respondents knew whether antibiotic-prophylaxis or "pain medication" was required before PTBD procedure. Only a few respondents were aware of the existence of a hospital protocol for PTBD management and its content. CONCLUSIONS: Nursing care for biliary catheters is not standardized nationwide, and consensus on management is lacking. An evidence-based guideline for PTBD management is advised for nursing care of patients with HPB diseases.


Biliary Tract Diseases/nursing , Clinical Competence/standards , Drainage/nursing , Liver Diseases/nursing , Nurses/standards , Pancreatic Diseases/nursing , Drainage/methods , Gastroenterology/standards , Health Knowledge, Attitudes, Practice , Humans , Netherlands , Surveys and Questionnaires
3.
Appl. cancer res ; 37: 1-8, 2017. tab
Article En | LILACS, Inca | ID: biblio-915022

Background: Pancreatic cancer has a poor prognosis. Patients might be better able to cope with their disease when the information is discussed that they consider most important. We investigated what questions pancreatic patients consider most important to address in the first weeks after diagnosis. Methods: We built a survey listing 84 questions and for each asked how important (range, 1­7) individuals who had received a certain or likely diagnosis of pancreatic cancer considered it that the question was addressed soon after diagnosis; patients who completed the survey 1 year or more after diagnosis were excluded. Mean perceived importance scores were used to rank order the questions in terms of importance. Results: Forty-seven pancreatic cancer patients participated. The participants considered receiving an answer to a median of 53 (range, 21­83) questions as important (score = 6) or very important (score = 7). The number was not significantly related to gender, age, education, or time since diagnosis. For 42/84 questions, average score was ≥6.0. Topics considered most important included diagnosis, likelihood of cure, treatment options, harms and procedures, prognosis if the disease were left untreated, and quality of life. For 67/84 questions, ≥1 participants indicated that answering the question should be avoided (Md = 1 participant, range, 1­5) and for 77/84 questions that it was not applicable (Md = 3.5 participants, range, 1­30). Conclusions: Pancreatic cancer patients consider a wide range of questions important to address after diagnosis, including those on sensitive topics. Doctors need to carefully dose information provision to avoid overloading patients. The findings can help to guide doctors and other information resources to provide relevant information to pancreatic cancer patients (AU)


Adult , Middle Aged , Aged , Pancreatic Neoplasms/diagnosis , Surveys and Questionnaires , Multicenter Study
4.
Ultrasound Med Biol ; 41(12): 3063-9, 2015 Dec.
Article En | MEDLINE | ID: mdl-26427339

The aim of this study is to provide a diagnostic performance evaluation of contrast-enhanced ultrasonography (CEUS) in detecting liver metastases in patients with suspected of pancreatic or periampullary cancer. Computed tomography (CT) is often insufficient for detection of liver metastases, but their presence plays a crucial role in the choice of therapy. Eighty-nine patients with suspected pancreatic or periampullary cancer were included in this prospective study with retrospective analysis. Patients underwent an abdominal CT and CEUS. Fifteen patients had liver metastases. The CT sensitivity was 73.3% (11/15), the specificity 93.2% (69/74), the positive predictive value (PPV) 68.8% (11/16) and the negative predictive value (NPV) 94.6% (69/73). Based on CEUS, the sensitivity was 80% (12/15), specificity 98.6% (73/74), PPV 92.3% (12/13) and NPV 96.1% (73/76). CEUS improved characterization of liver lesions in patients with suspected pancreatic or periampullary cancer compared with CT. CEUS can better detect benign liver lesions and distinguish false-positive or indeterminate CT results.


Common Bile Duct Neoplasms/pathology , Contrast Media , Image Enhancement , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/secondary , Pancreatic Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Ampulla of Vater/pathology , Female , Humans , Liver/diagnostic imaging , Male , Middle Aged , Prospective Studies , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Ultrasonography
5.
J Pain Symptom Manage ; 47(3): 518-30, 2014 Mar.
Article En | MEDLINE | ID: mdl-23880585

CONTEXT: Upper gastrointestinal cancer is associated with a poor prognosis. The multidimensional problems of incurable patients require close monitoring and frequent support, which cannot sufficiently be provided during conventional one to two month follow-up visits to the outpatient clinic. OBJECTIVES: To compare nurse-led follow-up at home with conventional medical follow-up in the outpatient clinic for patients with incurable primary or recurrent esophageal, pancreatic, or hepatobiliary cancer. METHODS: Patients were randomized to nurse-led follow-up at home or conventional medical follow-up in the outpatient clinic. Outcome parameters were quality of life (QoL), patient satisfaction, and health care consumption, measured by different questionnaires at one and a half and four months after randomization. As well, cost analyses were done for both follow-up strategies in the first four months. RESULTS: In total, 138 patients were randomized, of which 66 (48%) were evaluable. At baseline, both groups were similar with respect to clinical and sociodemographic characteristics and health-related QoL. Patients in the nurse-led follow-up group were significantly more satisfied with the visits, whereas QoL and health care consumption within the first four months were comparable between the two groups. Nurse-led follow-up was less expensive than conventional medical follow-up. However, the total costs for the first four months of follow-up in this study were higher in the nurse-led follow-up group because of a higher frequency of visits. CONCLUSION: The results suggest that conventional medical follow-up is interchangeable with nurse-led follow-up. A cost utility study is necessary to determine the preferred frequency and duration of the home visits.


Ambulatory Care/methods , Esophageal Neoplasms/therapy , Gastrointestinal Neoplasms/therapy , Home Care Services , Oncology Nursing/methods , Pancreatic Neoplasms/therapy , Aged , Ambulatory Care/economics , Ambulatory Care/psychology , Ambulatory Care Facilities/economics , Esophageal Neoplasms/economics , Esophageal Neoplasms/psychology , Female , Follow-Up Studies , Gastrointestinal Neoplasms/economics , Gastrointestinal Neoplasms/psychology , Home Care Services/economics , Humans , Male , Middle Aged , Nurses , Oncology Nursing/economics , Palliative Care/economics , Palliative Care/methods , Palliative Care/psychology , Pancreatic Neoplasms/economics , Pancreatic Neoplasms/psychology , Patient Satisfaction , Quality of Life , Surveys and Questionnaires
6.
Cancer ; 116(4): 830-6, 2010 Feb 15.
Article En | MEDLINE | ID: mdl-20029974

BACKGROUND: Adjuvant therapies for pancreatic and periampullary cancer reportedly achieve only a marginal survival benefit. In this randomized controlled trial, 120 patients with resected pancreatic or periampullary cancer received either adjuvant celiac axis infusion chemotherapy combined with radiotherapy (CAI/RT) or no adjuvant treatment. The objective of the study was to compare the quality of life (QoL) in patients who received CAI/RT after pancreatoduodenectomy with the QoL in patients who did not receive adjuvant treatment. METHODS: During and after CAI/RT, QoL was assessed using the European Organization for Research and Treatment of Cancer QoL Questionnaire C30 every 3 months during the first 24 months after randomization. RESULTS: Eighty-six percent of patients (n = 103) completed 1 or more questionnaires. In total, 355 questionnaires were completed. The results indicated that CAI/RT did not impair physical, emotional, or social functioning. During and after CAI/RT, patients had significantly less pain (P = .02) and less nausea and vomiting (P = .01). Overall QoL (global functioning) tended to be better (P = .08) after CAI/RT. CONCLUSIONS: Over a period of 24 months, CAI/RT improved QoL compared with observation alone in patients with resected pancreatic and periampullary cancer. This beneficial effect of CAI/RT was most prominent in the latter half of the follow-up.


Pancreatic Neoplasms/psychology , Pancreatic Neoplasms/therapy , Quality of Life , Adult , Aged , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Humans , Infusions, Intra-Arterial , Male , Middle Aged , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/radiotherapy , Pancreatic Neoplasms/surgery , Radiotherapy, Adjuvant , Time Factors , Treatment Outcome
...